Datamonitor surveyed 199 primary care physicians and specialists across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) on their type 2 diabetes treatment choices and prescribing behavior. Physicians in different markets favor different drug classes at different treatment lines, and there is wide variation in type 2 diabetes treatment and trends.
Features and benefits
* Follow the patient segmentation and treatment pathways for type 2 diabetes in each market
* Compare drug use across all therapy lines and single/combination treatment strategies
* Identify opportunities to consolidate patient share in the widely fragmented diabetes treatment algorithm.
* Gain insight into physicians’ perceptions on trends in use of key antidiabetic classes.
Physicians estimate that a mean of 37% of people with type 2 diabetes in the seven major markets remain undiagnosed. Of the diagnosed patients, 16% are not being treated with drugs. Datamonitor estimates that the adult type 2 diabetes drug-treated population in the seven major markets is close to 27 million patients.
Physicians report 278 different class combinations used across first line, second line, and third and later line. Patient treatment varies with individual response, lifestyle, and comorbidities. However, the top 10 combinations account for 47% of all combination-treated patients, suggesting the use of common approaches in managing diabetes.
Type 2 diabetes patients are fairly evenly split between first-line, second-line, and third-line and later therapies. Specialist diabetologists and endocrinologists report more later-line patients compared with primary care physicians (PCPs). While 75% of treatment at first line is monotherapy, combinations dominate later-line treatment.
Your key questions answered
* Delve into primary data from 199 seven major market physicians on current usage and future trends of type 2 diabetes therapies.
* Follow through the most used monotherapies and combination therapies at each therapy line, in each market.
* Identify the different opportunities in the type 2 diabetes treatment algorithm in each of the seven major markets.